Malignant Germ Cell Tumor — Clinical Trials

MONDO:000629017 active·7 recruitingLast updated: Mar 16, 2026, 5:29 PM

Trial Landscape

Malignant Germ Cell Tumor has a growing clinical research program, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment14

Procedure9

Biological Therapy2

Medical Device1

7 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 1

Phase 2

Phase 3

Sponsor Types

NIH8Academic/Other8Collaborative Network1

Trial Locations

United States15 trials

Puerto Rico9 trials

Australia6 trials

Canada4 trials

United Kingdom2 trials

India1 trial

Japan1 trial

New Zealand1 trial

Saudi Arabia1 trial

Russia1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

17 Trials

Phase 3Recruiting

NCT03067181

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Sponsor:Children's Oncology Group

United StatesStarted: May 2017Est. completion: Jun 2027Updated: Feb 2026

Phase 2Recruiting

NCT05969860

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Sponsor:Mayo Clinic

United StatesStarted: Aug 2023Est. completion: Jan 2027Updated: Feb 2026

Phase 2Recruiting

NCT07188441

Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.

Sponsor:Chengcheng Guo

ChinaStarted: Aug 2024Est. completion: Dec 2026Updated: Sep 2025

Phase 2Recruiting

NCT06418789

High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors

Sponsor:N.N. Petrov National Medical Research Center of Oncology

RussiaStarted: Mar 2024Est. completion: Mar 2029Updated: Aug 2025

Phase 1Recruiting

NCT04901702

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Sponsor:St. Jude Children's Research Hospital

United StatesStarted: Jun 2021Est. completion: Dec 2026Updated: Feb 2026

Phase 1Recruiting

NCT07218913

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

Sponsor:City of Hope Medical Center

United StatesStarted: Mar 2026Est. completion: Jan 2031Updated: Jan 2026

Phase 1Recruiting

NCT05857969

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Sponsor:Florida International University

United StatesStarted: Feb 2023Est. completion: Dec 2028Updated: Jul 2025

Phase 3Active, Not Recruiting

NCT02375204

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Sponsor:Alliance for Clinical Trials in Oncology

United StatesStarted: Aug 2015Est. completion: Jun 2031Updated: Jan 2025

Phase 2Active, Not Recruiting

NCT03213652

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Apr 2018Est. completion: Oct 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT03210714

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jun 2018Est. completion: Dec 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT03155620

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2017Est. completion: Jan 2027Updated: Feb 2026

Phase 2Active, Not Recruiting

NCT04195555

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2020Est. completion: May 2026Updated: Jan 2026

Phase 2Active, Not Recruiting

NCT02721732

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Sponsor:M.D. Anderson Cancer Center

United StatesStarted: Aug 2016Est. completion: Dec 2028Updated: Jan 2026

Phase 2Active, Not Recruiting

NCT04284774

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Oct 2020Est. completion: Sep 2027Updated: Dec 2025

Phase 2Active, Not Recruiting

NCT04320888

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2021Est. completion: Jun 2026Updated: Dec 2025

Phase 2Active, Not Recruiting

NCT03213704

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Aug 2017Est. completion: Oct 2026Updated: Dec 2025

Phase 2Active, Not Recruiting

NCT03698994

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Nov 2018Est. completion: Mar 2026Updated: Dec 2025

Stay informed about clinical trials for Malignant Germ Cell Tumor.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 16, 2026 at 5:29 PM

Malignant Germ Cell Tumor — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Trial Locations

17 Trials

Open Trials7

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.

High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Active Trials10

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)